Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InhaleRx Limited ( (AU:IRX) ) just unveiled an update.
InhaleRx reported progress across its clinical portfolio for the quarter ended 31 December 2025, underpinned by fresh funding and preparation for key trials. The company raised $857,730 through a placement and entitlement offer to support operating costs and extended its funding agreement with Linlithgow Family Office by $12.6 million to advance SRX-25 to Phase 3 readiness, strengthening its financial position for near- and mid-term development. Operationally, InhaleRx completed manufacturing of trial drugs for the Phase 2 trial of IRX-211 for breakthrough cancer pain and the Phase 1 trial of IRX-616a for panic disorder, executed clinical trial agreements with key Australian sites, and advanced protocol and documentation for the SRX-25 program. While the start of patient screening for the IRX-211 Phase 2 trial was delayed by site budget negotiations, these issues have now been resolved as the company prepares for first patient dosing, positioning its lead asset in a large and underserved cancer pain market where there are no FDA-approved non-opioid inhaled treatments and fentanyl-based rapid-onset options have recently been withdrawn in the US.
The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.
More about InhaleRx Limited
InhaleRx Limited is an Australian drug development company focused on novel inhaled and oral medicines targeting pain and mental health conditions. Its pipeline currently includes IRX-211, an inhaled treatment for breakthrough cancer pain, IRX-616a, an inhaled treatment for panic disorder, and SRX-25, an oral treatment for treatment-resistant depression, with a strategic aim of securing US FDA New Drug Approvals for each indication in sizeable, underserved markets such as cancer pain.
Average Trading Volume: 271,657
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.16M
For an in-depth examination of IRX stock, go to TipRanks’ Overview page.